TYK2 (Ab-1054) Antibody

What is TYK2 (Ab-1054) Antibody and what epitope does it recognize?

TYK2 (Ab-1054) Antibody is a rabbit polyclonal antibody specifically designed to target TYK2 (Tyrosine kinase 2), a member of the Janus kinases (JAKs) protein family. This antibody recognizes a specific peptide sequence around amino acids 1052-1056 (H-E-Y-Y-R) derived from Human TYK2 . The antibody detects endogenous levels of total TYK2 protein rather than specific phosphorylated forms, making it useful for general TYK2 expression studies . Researchers should note that this specificity distinguishes it from phospho-specific antibodies that recognize only activated forms of TYK2.

What are the primary applications for TYK2 (Ab-1054) Antibody?

TYK2 (Ab-1054) Antibody has been validated for multiple experimental applications, primarily:

• Enzyme-Linked Immunosorbent Assay (ELISA)

• Immunohistochemistry (IHC)

• Western Blotting (WB)

When using this antibody for Western Blot, researchers typically detect a specific band for TYK2 at approximately 130 kDa . For immunohistochemistry applications, the antibody effectively detects endogenous levels of total TYK2 protein in formalin-fixed, paraffin-embedded tissue samples . Optimal dilutions vary by application, with Western blotting typically using 1:500-1:1000 dilutions .

What species reactivity does TYK2 (Ab-1054) Antibody demonstrate?

The antibody has confirmed reactivity with TYK2 from multiple species:

• Human

• Mouse

• Rat

This cross-species reactivity makes the antibody versatile for comparative studies across different mammalian models . The conservation of the target epitope across species suggests evolutionary importance of this region of the TYK2 protein.

How should TYK2 (Ab-1054) Antibody be stored for optimal performance?

For long-term preservation, store the antibody at -20°C or -80°C . For short-term use (within a few weeks), storage at 4°C is acceptable . The antibody is typically supplied at 1.0mg/mL in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol . Researchers should avoid repeated freeze-thaw cycles as this can degrade antibody performance and lead to increased background signal .

How can I distinguish between TYK2 and other JAK family proteins in my experiments?

Distinguishing TYK2 from other JAK family members requires careful experimental design:

• Epitope specificity: TYK2 (Ab-1054) Antibody targets a unique peptide sequence (H-E-Y-Y-R) that differs from homologous regions in JAK1, JAK2, and JAK3 .

• Molecular weight verification: In Western blot applications, TYK2 appears at approximately 130 kDa, which can help distinguish it from other JAK family members with different molecular weights .

• Confirmatory approaches: For critical experiments, researchers should consider:

  • Using siRNA knockdown of TYK2 as a negative control

  • Comparing results with a second TYK2 antibody targeting a different epitope

  • Performing parallel detection with antibodies specific to other JAK family members

These strategies help ensure signal specificity when studying complex signaling pathways where multiple JAK proteins may be present.

What are the considerations when studying phosphorylation states of TYK2?

While TYK2 (Ab-1054) Antibody detects total TYK2 protein regardless of phosphorylation status, researchers interested in activation states should note:

• This antibody does not specifically detect phosphorylated forms of TYK2 .

• For phosphorylation studies, specialized antibodies like Anti-TYK2 (Phospho-Tyr1054) Antibody are required, which specifically recognize TYK2 when phosphorylated at tyrosine 1054 .

• Experimental design for phosphorylation studies should include:

  • Positive controls (cytokine-stimulated cells known to activate TYK2)

  • Phosphatase inhibitors in all buffers during sample preparation

  • Parallel detection of total TYK2 (using Ab-1054) and phospho-TYK2 (using phospho-specific antibodies)

This dual detection approach allows researchers to calculate the ratio of phosphorylated to total TYK2, providing more meaningful quantification of activation status than either measurement alone.

How can I optimize TYK2 (Ab-1054) Antibody for immunohistochemistry in different tissue types?

Optimizing IHC protocols for TYK2 detection across diverse tissue types requires systematic adjustment of several parameters:

• Antigen retrieval methods: Depending on tissue type and fixation conditions, choose between:

  • Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Enzymatic retrieval using proteinase K for heavily fixed tissues

• Antibody concentration: Begin with the recommended 1:500-1:1000 dilution , then titrate for optimal signal-to-noise ratio in your specific tissue.

• Incubation conditions:

  • Primary antibody incubation: Test both overnight incubation at 4°C versus 1-2 hours at room temperature

  • Secondary detection system: Select based on desired sensitivity (polymer-based systems typically offer higher sensitivity)

• Tissue-specific considerations:

  • For tissues with high endogenous peroxidase activity (e.g., liver, kidney), extend peroxidase blocking steps

  • For tissues with high background (e.g., brain), include additional blocking steps with normal serum matching the host of the secondary antibody

Recent digital image analysis techniques for quantifying TYK2 expression in formalin-fixed paraffin-embedded tissues can provide more objective assessment of staining intensity and distribution patterns .

What are the best practices for validating experimental results with TYK2 (Ab-1054) Antibody?

Robust validation of experimental findings using TYK2 (Ab-1054) Antibody should include:

• Antibody specificity controls:

  • Preabsorption with immunizing peptide to confirm binding specificity

  • TYK2 knockout or knockdown controls to verify absence of signal

  • Comparison with other validated TYK2 antibodies targeting different epitopes

• Technical controls for each application:

  • For Western blot: Molecular weight marker, positive control lysates (e.g., HeLa or K562 cell lines)

  • For IHC: Positive control tissues with known TYK2 expression, isotype control antibodies

  • For ELISA: Standard curve using recombinant TYK2 protein, background controls

• Reproducibility assessment:

  • Technical replicates to evaluate method consistency

  • Biological replicates to account for sample variation

  • Independent experimental repetition to confirm findings

These validation steps are essential for publication-quality data, particularly when studying novel aspects of TYK2 biology or pathology.

How should I design experiments to study TYK2 in the context of interferon signaling pathways?

TYK2 plays crucial roles in both type I and type III interferon signaling pathways . When investigating these pathways:

• Experimental design considerations:

  • Time course experiments: Monitor TYK2 phosphorylation and downstream signaling at multiple timepoints (5 min, 15 min, 30 min, 1 hr, 4 hr) after interferon stimulation

  • Dose-response relationships: Test multiple concentrations of interferons to determine threshold and saturation levels

  • Cell type specificity: Compare primary cells versus cell lines, as signaling dynamics may differ

• Recommended methodological approach:

  • Begin with Western blot using both TYK2 (Ab-1054) Antibody and phospho-specific TYK2 antibodies

  • Complement with functional readouts (e.g., STAT phosphorylation, interferon-stimulated gene expression)

  • Consider proximity ligation assays to study TYK2 interactions with receptor components

• Controls and comparative analyses:

  • Include JAK inhibitors as negative controls

  • Compare TYK2-dependent versus TYK2-independent interferon responses

  • Assess pathway activation in cells from different species using the cross-species reactivity of the antibody

This comprehensive approach helps delineate the specific contributions of TYK2 within complex cytokine signaling networks.

What are the considerations for multiplex immunofluorescence studies using TYK2 (Ab-1054) Antibody?

Multiplex immunofluorescence allows simultaneous detection of TYK2 alongside other proteins of interest:

• Conjugation options: TYK2 (Ab-1054) Antibody can be custom-conjugated with various fluorophores or reporter molecules:

• Protocol optimization for multiplex detection:

  • Sequential antibody application to minimize cross-reactivity

  • Careful selection of fluorophores to avoid spectral overlap

  • Extended blocking steps to reduce non-specific binding

  • Titration of each antibody individually before combining

• Analysis considerations:

  • Proper controls for spectral unmixing

  • Single-color controls for compensation settings

  • Software-based colocalization analysis for quantifying protein interactions

These approaches enable sophisticated studies of TYK2 colocalization with cytokine receptors or downstream signaling components in situ.

How can TYK2 (Ab-1054) Antibody be used to study hyperimmunoglobulin E syndrome (HIES)?

Mutations in TYK2 have been associated with hyperimmunoglobulin E syndrome (HIES), a primary immunodeficiency . For researchers investigating this connection:

• Experimental approach using TYK2 (Ab-1054) Antibody:

  • Expression analysis: Compare TYK2 protein levels in patient-derived versus healthy control cells

  • Localization studies: Assess whether disease-associated mutations alter TYK2 subcellular distribution

  • Protein stability analysis: Determine if mutations affect TYK2 half-life through cycloheximide chase experiments

• Patient sample considerations:

  • Use lymphocytes or fibroblasts from HIES patients with known TYK2 mutations

  • Apply immunohistochemistry to tissue biopsies to assess in vivo expression patterns

  • Combine with genetic data to correlate mutation type with protein expression levels

• Functional correlation:

  • Compare TYK2 protein expression with cytokine responsiveness

  • Assess relationship between TYK2 levels and IgE production

  • Evaluate TYK2-dependent antimicrobial immunity in patient cells

This approach helps clarify how TYK2 mutations contribute to HIES pathophysiology and may identify potential therapeutic targets.

What are the methodological considerations when using TYK2 (Ab-1054) Antibody in cancer research?

TYK2 signaling has emerging roles in various cancers, particularly through its effects on immune responses and cellular proliferation:

• Tumor tissue analysis protocols:

  • Optimize antigen retrieval for formalin-fixed paraffin-embedded tumor samples

  • Consider tissue microarrays for high-throughput screening across multiple tumor types

  • Develop scoring systems for TYK2 expression levels (low, medium, high) based on staining intensity and distribution

• Cell line investigations:

  • Compare TYK2 expression across cancer cell lines using Western blot analysis

  • Correlate expression with response to JAK inhibitors or immunotherapies

  • Develop TYK2 knockdown/knockout models to assess functional dependencies

• Digital pathology approaches:

  • Apply quantitative image analysis to objectively measure TYK2 expression

  • Correlate with clinical outcomes in patient cohorts

  • Integrate with other biomarker data for comprehensive tumor profiling

These methods can help identify patient subsets that might benefit from TYK2-targeted therapies or combination approaches.

How might TYK2 (Ab-1054) Antibody contribute to developing new therapeutic approaches?

As TYK2 emerges as a therapeutic target, this antibody can support several research avenues:

• Target validation studies:

  • Confirm TYK2 expression in tissues of interest before drug development

  • Assess TYK2 levels in responders versus non-responders to existing therapies

  • Identify patient subpopulations with altered TYK2 expression or localization

• Pharmacodynamic biomarker development:

  • Monitor changes in TYK2 expression or phosphorylation following experimental treatments

  • Develop immunohistochemistry protocols suitable for clinical trial tissue samples

  • Establish quantitative metrics for treatment-induced changes in TYK2 signaling

• Combination therapy research:

  • Evaluate TYK2 expression changes after treatment with complementary pathway inhibitors

  • Identify compensatory mechanisms that alter TYK2 levels following targeted therapies

  • Screen for synergistic drug combinations that modulate TYK2-dependent pathways

These applications can accelerate translational research on TYK2-targeted therapeutics for autoimmune diseases, cancer, and other conditions.